CIK 0001582313 · Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- EIN
- 980661854
- Phone
- (604) 484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-09-01 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Shares withheld for taxes | −6,121 | $38.81 | $238K | 60,675 |
| 2022-09-01 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Sale | −35,103 | $38.03 | $1.3M | 25,572 |
| 2022-09-01 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Sale | −8,776 | $38.80 | $341K | 16,796 |
| 2022-09-01 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Option exercise · Stock Option (Right to Buy) | −50,000 | 0 | ||
| 2022-08-31 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Option exercise | +17,488 | $2.67 | $47K | 34,720 |
| 2022-08-31 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Option exercise | +5,000 | $4.75 | $24K | 39,720 |
| 2022-08-31 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Shares withheld for taxes | −1,572 | $37.86 | $60K | 38,148 |
| 2022-08-31 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Sale | −21,352 | $38.57 | $824K | 16,796 |
| 2022-08-31 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Option exercise · Stock Options (Right to Buy) | −17,488 | 0 | ||
| 2022-08-31 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Option exercise · Stock Options (Right to Buy) | −5,000 | 0 | ||
| 2022-08-16 | PIMSTONE SIMON N. Director | Sale | −32,058 | $38.29 | $1.2M | 26,000 |
| 2022-08-16 | PIMSTONE SIMON N. Director | Sale | −20,000 | $38.87 | $777K | 6,000 |
| 2022-08-15 | PIMSTONE SIMON N. Director | Sale | −33,942 | $37.76 | $1.3M | 58,058 |
| 2022-08-12 | EMPFIELD JAMES R. EVP, Drug Discovery | Option exercise | +20,000 | $3.10 | $62K | 30,000 |
| 2022-08-12 | EMPFIELD JAMES R. EVP, Drug Discovery | Option exercise | +45,000 | $4.75 | $214K | 75,000 |
| 2022-08-12 | EMPFIELD JAMES R. EVP, Drug Discovery | Shares withheld for taxes | −7,257 | $38.02 | $276K | 67,743 |
| 2022-08-12 | EMPFIELD JAMES R. EVP, Drug Discovery | Sale | −35,868 | $38.08 | $1.4M | 31,875 |
| 2022-08-12 | EMPFIELD JAMES R. EVP, Drug Discovery | Sale | −21,875 | $38.68 | $846K | 10,000 |
| 2022-08-12 | EMPFIELD JAMES R. EVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) | −20,000 | 0 | ||
| 2022-08-12 | EMPFIELD JAMES R. EVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) | −45,000 | 0 |
Page 15 of 16 · 308 trades